Pediatrics
Conference Coverage
Little change in rheumatology faculty coverage in pediatric residency programs in nearly 20 years
There has been little improvement in addressing the shortage of pediatric rheumatologists over the past 2 decades, boding poorly for future...
Feature
Biosimilars and patients: Discussions should address safety, cost, and anxiety about change
Physicians can respond to pushback from patients on switching to a biosimilar by offering resources and discussing options for both biosimilar and...
News from the FDA/CDC
FDA approves new formulation of Hyrimoz adalimumab biosimilar
The agency approved a higher-concentration formulation of Hyrimoz for its previous indications, including rheumatoid arthritis and psoriasis.
Feature
What’s holding back physicians from prescribing biosimilars? Four specialties weigh in
Physicians surveyed from four different specialties reported that they were generally comfortable prescribing biosimilars, but greater discounts...
Commentary
A doctor intervenes in a fiery car crash
‘While all of the children were concerning to me, I identified one in particular: the 5-year-old boy.’
Feature
COVID emergency orders ending: What’s next?
There will be cost-sharing changes for COVID-19 vaccines, testing, and certain treatments.
Commentary
75 years: A look back on the fascinating history of methotrexate and folate antagonists
Dr. David Warmflash recounts how the meandering path of early research into chemotherapy for hematologic malignancies later led to methotrexate’s...
From the Journals
Abnormal bleeding common among youth with joint hypermobility
Study suggests that children with generalized joint hypermobility should be routinely screened for abnormal bleeding symptoms and referred as...
From the Journals
New study offers details on post-COVID pediatric illness
This pediatric illness occurs 2-6 weeks after being infected with COVID-19.
Latest News
FDA will review pediatric indication for roflumilast cream
The indication under review is for treating psoriasis in children aged 2-11 years.
News from the FDA/CDC
FDA approves Idacio as eighth adalimumab biosimilar in U.S.
Data for Idacio (adalimumab-aacf) showed safety, efficacy, and immunogenicity similar to Humira.